Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedJun 12, 2026
DataAggregated Company Financials
Companies17
  • 7D1.0%
  • 3M-5.5%
  • 1Y17.4%
  • YTD0.4%

Last week, the Pharma industry hasn't moved much but GSK is up 3.2% in that time. The past year has been better, since the industry has gained 17% in that time. As for the next few years, earnings are expected to grow by 10% per annum.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 12 Jun 2026UK£324.1bUK£92.0bUK£15.8b17.8x20.5x3.5x
Sun, 10 May 2026UK£315.7bUK£91.3bUK£15.7b17.6x20.1x3.5x
Tue, 07 Apr 2026UK£362.2bUK£91.4bUK£15.7b20x23x4x
Thu, 05 Mar 2026UK£358.1bUK£90.8bUK£15.7b21.6x22.9x3.9x
Sat, 31 Jan 2026UK£325.6bUK£88.5bUK£14.5b23.7x22.5x3.7x
Mon, 29 Dec 2025UK£323.1bUK£89.2bUK£14.6b21.8x22.2x3.6x
Wed, 26 Nov 2025UK£329.9bUK£90.4bUK£14.8b21.9x22.3x3.6x
Fri, 24 Oct 2025UK£297.5bUK£88.1bUK£11.8b20.6x25.3x3.4x
Sun, 21 Sep 2025UK£271.9bUK£87.6bUK£11.7b18.7x23.2x3.1x
Tue, 19 Aug 2025UK£278.7bUK£87.5bUK£11.7b21.7x23.8x3.2x
Thu, 17 Jul 2025UK£258.5bUK£86.7bUK£10.7b25.8x24.3x3x
Sat, 14 Jun 2025UK£274.4bUK£86.2bUK£10.6b27.2x25.9x3.2x
Mon, 12 May 2025UK£258.4bUK£87.2bUK£10.7b26.3x24.2x3x
Wed, 09 Apr 2025UK£255.1bUK£88.2bUK£9.8b29.2x26x2.9x
Fri, 07 Mar 2025UK£291.4bUK£87.9bUK£9.6b29.1x30.3x3.3x
Sun, 02 Feb 2025UK£241.2bUK£75.9bUK£7.8b33.6x30.7x3.2x
Tue, 31 Dec 2024UK£223.1bUK£75.5bUK£7.8b31.1x28.6x3x
Thu, 28 Nov 2024UK£225.8bUK£75.0bUK£7.7b31.9x29.2x3x
Sat, 26 Oct 2024UK£247.0bUK£72.5bUK£9.1b29.9x27.2x3.4x
Mon, 23 Sep 2024UK£252.7bUK£71.5bUK£8.9b37.8x28.3x3.5x
Wed, 21 Aug 2024UK£275.9bUK£72.3bUK£9.0b41.1x30.6x3.8x
Fri, 19 Jul 2024UK£258.0bUK£70.8bUK£9.5b35.5x27.3x3.6x
Sun, 16 Jun 2024UK£267.2bUK£71.6bUK£9.6b31.5x27.9x3.7x
Tue, 14 May 2024UK£273.1bUK£72.0bUK£9.6b37.2x28.4x3.8x
Thu, 11 Apr 2024UK£242.0bUK£71.1bUK£9.7b32.5x24.8x3.4x
Sat, 09 Mar 2024UK£235.2bUK£70.1bUK£9.7b31x24.3x3.4x
Mon, 05 Feb 2024UK£237.0bUK£69.8bUK£9.5b35.2x24.8x3.4x
Wed, 03 Jan 2024UK£239.1bUK£69.1bUK£10.7b35.8x22.3x3.5x
Fri, 01 Dec 2023UK£226.1bUK£69.1bUK£10.7b33.6x21.1x3.3x
Sun, 29 Oct 2023UK£229.1bUK£70.8bUK£10.4b54x22.1x3.2x
Tue, 26 Sep 2023UK£250.4bUK£70.6bUK£10.4b55.8x24.2x3.5x
Thu, 24 Aug 2023UK£236.5bUK£69.0bUK£10.2b53.5x23.3x3.4x
Sat, 22 Jul 2023UK£237.3bUK£67.4bUK£7.8b52x30.3x3.5x
Mon, 19 Jun 2023UK£251.8bUK£67.4bUK£7.9b55.5x32x3.7x
Price to Earnings Ratio

32x


Total Market Cap: UK£251.8bTotal Earnings: UK£7.9bTotal Revenue: UK£67.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 25.3x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 20.5x which is lower than its 3-year average PE of 25.3x.
  • The industry is trading close to its 3-year average PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 11% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market-0.78%
Healthcare0.79%
Pharma0.97%
Pharma0.97%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GSK GSKUK£19.633.2%
+UK£2.4b		26.7%PE13.4x
AZN AstraZenecaUK£135.780.2%
+UK£372.2m		23.1%PE27.2x
HLN HaleonUK£3.341.3%
+UK£372.1m		-16.5%PE17.8x
HIK Hikma PharmaceuticalsUK£14.821.5%
+UK£46.9m		-30.9%PE10.5x
STX Shield TherapeuticsUK£0.0626.9%
+UK£4.3m		148.0%PS1.8x

Latest News

GSK
UK£19.63
GSK
7D
3.2%
1Y
26.7%
POLB
UK£0.077
Poolbeg Pharma
7D
-8.3%
1Y
123.2%
HCM
UK£1.69
HUTCHMED (China)
7D
-1.9%
1Y
-35.6%
Narrative Update • Jun 11

HCM: Late Stage Hematology And Oncology Readouts Will Drive Reassessment

Analysts have trimmed their price target on HUTCHMED (China) from £5.62 to £5.20, reflecting updated assumptions around a higher discount rate, slightly stronger revenue growth expectations, a lower projected profit margin, and a higher future P/E multiple. What's in the News China NMPA approved the New Drug Application for TYVYT (sintilimab) plus ELUNATE (fruquintinib) for patients with locally advanced or metastatic renal cell carcinoma after prior VEGFR TKI therapy and without prior PD 1 or PD L1 treatment, based on the FRUSICA 2 registration study.
AZN
UK£135.78
AstraZeneca
7D
0.2%
1Y
23.1%
FUM
UK£0.0055
Futura Medical
7D
-19.7%
1Y
-93.9%
HIK
UK£14.82
Hikma Pharmaceuticals
7D
1.5%
1Y
-30.9%
STX
UK£0.062
Shield Therapeutics
7D
6.9%
1Y
148.0%
Narrative Update • Jun 05

STX: Pediatric And Japan Trial Milestones Will Drive Future Earnings Upside

Shield Therapeutics' analyst price target is now set at £0.14. Analysts attribute this level to unchanged fair value, discount rate and P/E assumptions, combined with modest adjustments to revenue growth and profit margin forecasts.
HLN
UK£3.34
Haleon
7D
1.3%
1Y
-16.5%
IMM
UK£0.046
ImmuPharma
7D
3.0%
1Y
73.5%
EAH
UK£0.92
ECO Animal Health Group
7D
-1.1%
1Y
46.0%
THAT
UK£0.0057
Thalia Therapeutics
7D
-4.2%
1Y
21.1%
AGY
UK£0.08
Allergy Therapeutics
7D
-10.1%
1Y
21.2%
NFX
UK£0.002
Nuformix
7D
19.9%
1Y
97.1%
SAR
UK£0.23
Sareum Holdings
7D
-2.1%
1Y
64.3%